Remove 2020 Remove Pharmaceutical manufacturing Remove Safety
article thumbnail

PhRMA lies to protect pharma profits

World of DTC Marketing

In 2020 JAMA found that the estimated median capitalized research and development cost per product was $985 million, counting expenditures on failed trials. Meanwhile, the top 25 pharmaceutical companies reported a “healthy average operating margin of 22 percent” at the end of 2017, according to an analysis by GlobalData.

Pharma 255
article thumbnail

Tackling fake pharmaceuticals: an industry united against counterfeit products

European Pharmaceutical Review

Consequently, pharmaceutical manufacturers risk their reputation if impersonating products fail to deliver the expected quality or health impact. For manufacturers, this allows for greater protection of products courtesy of real-time tracking data and the ability to refine and secure supply chains by spotting weak links.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Top-10 ways for Pharma to leverage AI according to…AI

Impetus Digital

Manufacturing Optimization While the manufacturing industry lags behind others in terms of AI uptake, there is no shortage of potential ways to leverage this technology. Regulatory Compliance Regulatory frameworks are continuously evolving in the pharmaceutical industry.

Pharma 95
article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

Pharmaceutical manufacturers have submitted Citizen Petitions raising safety or efficacy concerns about proposed competing generic and biosimilar products, and such submissions often delay FDA approval of the proposed products while the FDA resolves the pending petitions. pdf; 21 C.F.R. 562, 117th Cong. §

article thumbnail

Top 5 Emerging Trends in Pharma Industry

Medico Reach

The global pharmaceutical manufacturing market stood at USD 405.52 billion in 2020 and will project growth of USD 4.18 billion during 2020-2024. The paradigm shift towards integrated, intelligent, and data-rich technologies is propelling the growth of medicines manufacturing. from 2023 to 2030.

Pharma 52
article thumbnail

Cleanroom microbiology: single-temperature incubation for EM

European Pharmaceutical Review

To say that 25°C is the only valid temperature is erroneous, but in view of the data generated in our context, it remains the optimum temperature for the detection of contamination in our production environment, thus guaranteeing drug quality and, ultimately, patient safety. Automation has proved its worth in terms of early colony detection.

article thumbnail

Everything You Need to Know About Market Access in China

PM360

During the application stage, manufacturers should formulate principles and prepare a value dossier which is structuralized in a similar way as a classic payer value story. The content of the value dossier should consist of product introduction, effectiveness, novelty, safety, economic value, and equity. Kapusniak, C. Rémuzat, Y.

Marketing 105